

Our commitment goes beyond investment



Areas of focus



Oncology

- Multiple myeloma
- B-cell malignancies
- Myeloid malignancies
- Bladder cancer
- Lung cancer
- Prostate cancer
- Immune therapy



Immunology

- Immunodermatology
- Gastrointestinal
- Rheumatology
- Autoantibody and maternal-fetal



Neuroscience

- Neuropsychiatry
- Neurodegenerative disorders
- Ophthalmology

2025 portfolio M&As

AETION.

May 2025:

Undisclosed Terms, Datavant

capstantx™

June 2025:

\$2.1B, AbbVie

Paige

August 2025:

\$81.25M, Tempus

2025 private investments

RESOLVE 



PRAZER
THERAPEUTICS

STYLUS


 EpiBiologics

Link
Cell Therapies

Citrill

 cellularorigins

Biotech investment team



Chris Picariello
President, JJDC
New Brunswick, NJ



Nadiya Ishnazarova
Principal,
Venture Investments
Netherlands



Fiona MacLaughlin
Vice President,
Venture Investments
London, UK



Sanjay Mistry
Vice President,
Venture Investments,
New Company Creation
San Diego, CA



Nancy Ondovik
Principal,
New Company Creation
New Brunswick, NJ




Kyle O'Neil
Analyst,
Venture Investments
Cambridge, MA



Lior Teitelbaum
Principal,
Venture Investments
San Francisco, CA



Andres Tellez
Principal,
New Company Creation
Cambridge, MA



Wei Wu
Principal,
Venture Investments
San Francisco, CA



Asish Xavier
Vice President,
Venture Investments
San Francisco, CA

Johnson & Johnson

JJDC

Oncology



Combining antibody engineering & radiotherapeutics to attack cancer in new ways: <https://abderatx.com/>
DLL3 radiopharmaceutical program in Phase 1
San Francisco, CA (Sanjay Mistry)



Pioneering a new class of small molecule precision cancer therapies: <https://accenttx.com/>
DHX9 and KIF18A inhibitors in Phase 1/2 studies for solid tumors
Cambridge, MA (Andres Tellez)



Transforming immune cell redirection for solid tumors and I&I
DLL3xVB17 redirector in IND-enabling stage for solid tumors
San Diego, CA (Andres Tellez)



Developing anchored-drug conjugates: <https://ankyratx.com/>
Alum X IL-12 for intra-tumoral delivery to solid tumors
Cambridge, MA (Andres Tellez)



Exploring direct cell reprogramming technologies to develop cancer immunotherapies: <https://www.asgardthx.com/>
Published proof-of-concept data for lead program
Lund, Sweden (Nadiya Ishnazarova)




Creating the next-generation of precision immunotherapies: <https://brightpeaktx.com/>
First patient dosed in solid tumors
Del Mar, CA (Asish Xavier)



Advancing bispecific antibodies to degrade disease-causing extracellular proteins: <https://www.epibiologics.com/>
Lead bispecific antibody for EGFR in IND-enabling studies
San Francisco, CA (Wei Wu)



Developing first-in-class small molecule inhibitors for the precision treatment of cancer: <https://flindrtx.com/>
Published proof-of-concept data on lead target, (HOIP)
Oss, Netherlands (Fiona MacLaughlin)



Multiple ADC programs using a powerful lego-like platform comprising of dozens of linkers and novel payloads: <http://www.dacbiotech.com/en/>
Hangzhou, China (Wei Wu)



An oncology cell therapy company: <https://linkcelltx.com/>
Lead program for treatment of renal cell carcinoma, IND & Ph I in 2026
San Francisco, CA (Lior Teitelbaum)
[Press release here](#)



Discovery of best and first-in-class bifunctional degraders for cancer: <https://www.paqtx.com/>
Cambridge, MA (Asish Xavier)



Creating new bispecific antibodies that engage the immune system: <https://www.rondotx.com/>
Lead CD28 x Nectin-4 antibody expected in clinic by 2026
San Francisco, CA (Asish Xavier)



Developing transformative in vivo genetic medicines: <https://www.stylusmedicine.com/>
Cambridge, MA (Andres Tellez)

Immunology



Pioneering the development of tissue-targeted genetic therapies with Centyrins: <https://www.arobiotx.com/>
Lead program targeting Gys1, for Pompe Disease, in Phase 1
Philadelphia, PA (Chris Picariello)



Transformative targeting of Neutrophil Extracellular Traps for immune-mediated inflammatory diseases: <https://citryll.com/>
Main program in Phase 2a trials in RA and HS
Oss, Netherlands (Fiona MacLaughlin)



New therapeutics for cancer & inflammatory diseases based on fibroblast biology: <https://www.mestagtherapeutics.com/>
Bispecific FAP-LTBR agonist in solid tumors in Pre-IND studies
Cambridge, UK (Fiona MacLaughlin)



A comprehensive target ID, validation, and drug discovery platform for the resolution of inflammation
Undisclosed lead program in discovery for I&I indications
Boston, MA (Andres Tellez)



Decoding human tissue biology by mapping Treg behavior to create revolutionary therapeutics: <https://trex.bio/>
TNFR2 agonist program in Phase 1
San Francisco, CA (Sanjay Mistry)

Neuroscience



Developing new medicines to block brain autoantibodies: <https://www.arialsrx.com/>
Program for Anti-NMDA receptor encephalitis, in Phase 1
San Diego, CA (Asish Xavier)



Targeted gene delivery for CNS disease: <https://aviadobio.com/>
Gene therapy program for progranulin, in Phase 1b
London, UK (Fiona MacLaughlin)



Novel SpiDEM degraders for treating neurodegenerative diseases and cancer: <http://prazertx.com>
PRX302 at lead optimization stage for Alzheimer's
Seoul, South Korea (Wei Wu)

Platform



Commercializing AI-enabled predictive & prognostic cancer tests, including the FDA approved ArteraAI Prostate Test: <https://artera.ai/>
San Francisco, CA (Nancy Ondovik)



Developing the next generation of cell and gene therapy manufacturing solutions: <https://www.astraveus.com/>
Paris, France (Fiona MacLaughlin)



Enabling patient access to cell therapy at scale: <https://cellularorigins.com/>
Melbourn, UK (Asish Xavier)



Developing a circular RNA-based platform and programs for multiple therapeutic areas: <http://m.circodebio.cn/en/>
Shanghai, China (Wei Wu)



Decoding the regulatory genome to deliver first-in-class therapies: <https://nucleome.com/>
Oxford, UK (Nadiya Ishnazarova)



Ultrasound-guided nonviral gene therapy: <https://sonothera.com/>
San Francisco, CA (Lior Teitelbaum)

Special Ophthalmology



Developing therapeutics to protect and improve vision in retinal diseases: <https://www.onltherapeutics.com/>
Program targeting Fas-mediated signaling, is Phase 2 ready
Ann Arbor, MI (Asish Xavier)



Focused on therapeutics for ocular diseases: <https://perceivebio.com/>
Lead program in clinical studies in Geographic Atrophy
San Francisco, CA (Lior Teitelbaum)



Focused on therapeutics for ocular diseases: <https://perceivebio.com/>
Preclinical small molecule neuroprotective therapies for glaucoma and other ophthalmic diseases
San Francisco, CA (Lior Teitelbaum)